All Clinical Trials
Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov.
332 trials found
Drug |
NCT# |
||
|---|---|---|---|
| Avapritinib or Regorafenib | (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST | 3 |
|
| Vorinostat + Bortezomib | Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors | 1 |
|
| HER-2 B Cell Peptide | Vaccine Therapy in Treating Patients With Metastatic Solid Tumors | 1 |
|
| Nilotinib and Imatinib | Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST) | 2 |
|
| MSC1936369B + SAR245409 | Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors | 1 |
|
| Dasatinib (BMS-354825) | Trial of Dasatinib in Advanced Sarcomas | 2 |
|
| Imatinib + Sunitinib + Regorafenib | Treatment Response Evaluation in Gastrointestinal Stromal Tumor (GIST) Patients | 4 |
|
| Everolimus | Treatment of Patients With RAD001 Who Have Progressive Sarcoma | 2 |
|
| Nilotinib | Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib. (OPEN) | 2 |
|
| Imatinib + RAD001 | Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate | 2 |
|
| Imatinib | Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST | 3 |
|
| Imatinib | The Stop-GIST Trial: Discontinuation of Imatinib in Patients With Oligo-metastatic GIST | 2 |
|
| AZD2171 (cediranib) | The Biological Activity of AZD2171 in GIST | 2 |
|
| CB-839 | Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study | 2 |
|
| Rogaratinib | Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST) | 2 |
|
| Cixutumumab + Temsirolimus | Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma | 2 |
|
| Temozolomide | Temozolomide in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors | 2 |
|
| Temozolomide | Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor | 2 |
|
| Nilotinib | Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST) | 2 |
|
| Symptom Inventory for Gastrointestinal Stromal Tumors | |||
| Sunitinib + Radiation | Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer | 2 |
|
| Surgery | Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor | 2 |
|
| Surgery | Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis | ||
| SU5416 | SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas | 2 |
|
| Sunitinib | SU011248 in Treating Patients With Malignant Gastrointestinal Stromal Tumor | 3 |
|
| Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors | 4 |
||
| AZD2171 | Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours | 2 |
|
| AT13387 | Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors | 1 |
|
| Sunitinib or Sorafenib | Study on the Influence of Sunitinib and Sorafenib on Fatigue, Quality of Life and Depression in Patients With Metastatic Renal Cell Cancer or Gastrointestinal Stromal Tumor (GIST) | ||
| XL820 | Study of XL820 in Adults With Solid Tumors | 1 |
|
| XL820 | Study of XL820 Given Orally Daily to Subjects With Solid Tumors | 1 |
|
| XL228 | Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies | 1 |
|
| EDO-S101 | Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors | 1/2 |
|
| XL765 | Study of the Safety and Pharmacokinetics of XL765 in Adults With Solid Tumors | 1 |
|
| XL147 | Study of the Safety and Pharmacokinetics of XL147 in Adults With Solid Tumors | 1 |
|
| CB-839 | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | 1 |
|
| Sunitinib | Study Of SU011248 Administered In A Daily Regimen In Patients With Gastrointestinal Stromal Tumor | 2 |
|
| STA-9090 | Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors | 1 |
|
| STA-9090 | Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors | 1 |
|
| Regorafenib (BAY 73-4506) | Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID) | 3 |